Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/26862
Title: | Associations of metabolic syndrome in SLE. | Authors: | Morand E. ;Vincent F.;Hoi A. ;Apostolopoulos D. | Monash Health Department(s): | Rheumatology | Institution: | (Apostolopoulos, Hoi, Morand) Department of Rheumatology, Monash Health, Melbourne, VIC, Australia (Vincent) Centre for Inflammatory Diseases, Monash University, Clayton, VIC, Australia (Hoi) Department of Medicine, Monash University, Faculty of Medicine Nursing and Health Sciences, Clayton, VIC, Australia | Issue Date: | 27-Mar-2021 | Copyright year: | 2020 | Publisher: | BMJ Publishing Group | Place of publication: | United Kingdom | Publication information: | Lupus Science and Medicine. 7 (1) (no pagination), 2020. Article Number: e000436. Date of Publication: 13 Nov 2020. | Journal: | Lupus Science and Medicine | Abstract: | Objectives To characterise the prevalence and associations of metabolic syndrome (MetS) in a multiethnic cohort of patients with SLE. Methods Using a standardised protocol, baseline demographics, per visit disease activity (Systemic Lupus Erythematosus Disease Activity Index-2K) and treatment data, and annual recording of organ damage accrual (Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC-ACR) Damage Index) were captured on patients with SLE from a single tertiary centre. The presence of MetS, defined using modified updated joint consensus criteria, was assessed at the final visit from patient records. Serum concentrations of adipocytokines were measured by Quantibody. Results 116 patients, with median (Q1, Q3) age at enrolment of 39.5 (31.4-51.1) years and disease duration of 6.1 (1.4-12) years, were followed for a median of 6.7 (4.1-8.1) years. The prevalence of MetS was 29% (34/116), while the prevalence of MetS components varied: hypertension (59%), low high-density lipoproteins (HDLs) (51%), hypertriglyceridaemia (32%), obesity (16%) and hyperglycaemia (22%). In univariable analysis, MetS was associated with baseline organ damage (OR 4.34; 95% CI 1.80 to 10.48; p<0.01) and organ damage accrual (OR 2.34; 95% CI 1.02 to 5.36; p=0.04) but not with disease activity. In multivariable analysis, baseline organ damage remained significantly associated with MetS (adjusted OR 3.36; 95% CI 1.32 to 8.59; p=0.01). Glucocorticoid use was not associated with MetS or any of its five components. High serum concentrations of resistin were significantly negatively associated with MetS (OR 0.17; 95% CI 0.04 to 0.70; p=0.014). Conclusion MetS was common in a multiethnic cohort of patients with SLE, with the most frequent components being hypertension and low HDL. An independent association was found between MetS and organ damage but not glucocorticoid exposure or disease activity.Copyright © | DOI: | http://monash.idm.oclc.org/login?url= http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1136/lupus-2020-000436 |
ISSN: | 2053-8790 (electronic) | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/26862 | Type: | Article | Subjects: | middle aged multivariate analysis obesity odds ratio organ injury prevalence priority journal protein blood level *systemic lupus erythematosus univariate analysis young adult adipocytokine/ec [Endogenous Compound] glucocorticoid high density lipoprotein/ec [Endogenous Compound] hydroxychloroquine immunosuppressive agent prednisolone resistin/ec [Endogenous Compound] female adult article cohort analysis confidence interval demography *disease association disease duration human human tissue hyperglycemia hypertension hypertriglyceridemia major clinical study male *metabolic syndrome X human tissue hyperglycemia hypertension hypertriglyceridemia major clinical study male *metabolic syndrome X middle aged multivariate analysis obesity odds ratio organ injury Article priority journal protein blood level *systemic lupus erythematosus univariate analysis young adult adult prevalence cohort analysis confidence interval demography *disease association disease duration female human |
Type of Clinical Study or Trial: | Observational study (cohort, case-control, cross sectional or survey) |
Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.